This article excerpt was originally published on the PhRMA website.
On January 31st, 2019, the Pharmaceutical Research and Manufacturers of America (PhRMA) elected three new officers to its board of directors. Olivier Brandicourt, CEO, Sanofi, became chairman of the PhRMA board of directors. Giovanni Caforio, M.D., chairman of the Board and CEO, Bristol-Myers Squibb Company was named chairman-elect and David Ricks, chairman and CEO, Eli Lilly and Company assumed the role of board treasurer.
Brandicourt formerly held the position of chairman-elect of the board and succeeds Robert A. Bradway, chairman and CEO, Amgen Inc. as PhRMA board chairman.
Brandicourt has served as CEO, Sanofi, since April 2015. Brandicourt joined Sanofi from Bayer Healthcare AG where he served as CEO from 2013 until 2015. Prior to joining Bayer Healthcare, Brandicourt worked at Pfizer for 13 years, where he served as a member of the executive leadership team and as president and general manager of the emerging markets and established products business units. He is an honorary member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York. Brandicourt studied medicine at the University of Paris V where he specialized in infectious diseases and tropical medicine and holds an advanced degree in cellular and immunological pathophysiology from the Paris Descartes University. Brandicourt also received a master’s degree in biology from the University of Paris XII.
Dr. Caforio has served as CEO of Bristol-Myers Squibb since May 2015 and became chairman of the board of directors in May 2017. Dr. Caforio received his medical degree from the University of Rome and joined Bristol-Myers Squibb in Italy in 2000. He advanced through a series of roles in Europe and the United States, becoming president of the U.S. commercial organization in 2011. He was named chief commercial officer in 2013 and became chief operating officer in 2014. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable and the CEO Roundtable on Cancer.
Ricks has served as CEO of Lilly since January 1, 2017 and became chairman of the board of directors on June 1, 2017. A 20-year Lilly veteran, he previously served as president of Lilly Bio-Medicines and as president of Lilly USA, the company’s largest affiliate. Ricks also served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, and general manager of Lilly Canada after roles as director of pharmaceutical marketing and national sales director in that country. He is the president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and serves on the board of the Central Indiana Corporate Partnership, the Elanco Board of Directors and the Adobe Board of Directors.
Ricks is a graduate of Purdue University and earned his MBA from Indiana University.